EUVIMEDEUVIMED entdecken
Crossref

Discovery of New thieno[2,3- d ]pyrimidines as EGFR Tyrosine Kinase Inhibitors for Cancer Treatment

Eman A Sobh iD, Mohammed A Dahab iD, Eslam B Elkaeed iD, Aisha A Alsfouk iD, Ibrahim M Ibrahim iD, Ahmed M Metwaly iD, Ibrahim H Eissa iD

Future Medicinal Chemistry · 2023

DOI: 10.4155/fmc-2023-0086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2023. Verfasst von Eman A Sobh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Princess Nourah Bint Abdulrahman University, AlMaarefa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

EGFR has been considered a vital molecular target in cancer management.

Aim

The discovery of new thieno[2,3-d]pyrimidine derivatives as EGFR tyrosine kinase inhibitors.

Methods

Nine derivatives were designed, synthesized and subjected to in vitro and in silico studies.

Results

Compound 7a significantly inhibited the growth of HepG2 and PC3 cells for both EGFR wild-type and EGFRT790M. Compound 7a caused a significant apoptotic effect, arresting HepG2 cells' growth in the S and G2/M phases. Docking and molecular dynamics simulation studies confirmed the correct and stable binding modes of the synthesized compounds against the active sites.

Conclusion

Compound 7a is a promising dual EGFR inhibitor for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLung NeoplasmsHumansStructure-Activity RelationshipErbB ReceptorsTyrosine Kinase InhibitorsPyrimidinesDrug Screening Assays, AntitumorProtein Kinase InhibitorsMutationCell ProliferationMolecular Docking SimulationMolecular StructureCell Line, Tumor

Stichwörter der Autor:innen

EGFR TKIsMD simulationsanticancerdockingthieno[2,3-d]pyrimidine

Substanzen

ErbB ReceptorsTyrosine Kinase InhibitorsPyrimidinesProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.
  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, 13713, Saudi Arabia.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, PO Box 84428, Riyadh, 11671, Saudi Arabia.
  • Biophysics Department, Faculty of Science, Cairo University, Cairo, 12613, Egypt.
  • Pharmacognosy & Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.

ORCID-Profile: Eman A Sobh, Mohammed A Dahab, Eslam B Elkaeed, Aisha A Alsfouk, Ibrahim M Ibrahim, Ahmed M Metwaly, Ibrahim H Eissa

Förderung

  • Princess Nourah Bint Abdulrahman University
  • AlMaarefa University

Zitieren

APA

Sobh, E. A., Dahab, M. A., Elkaeed, E. B., Alsfouk, A. A., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2023). Discovery of New thieno[2,3- d ]pyrimidines as EGFR Tyrosine Kinase Inhibitors for Cancer Treatment. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2023-0086

Vancouver

Sobh EA, Dahab MA, Elkaeed EB, Alsfouk AA, Ibrahim IM, Metwaly AM, et al. Discovery of New thieno[2,3- d ]pyrimidines as EGFR Tyrosine Kinase Inhibitors for Cancer Treatment. Future Medicinal Chemistry. 2023. doi:10.4155/fmc-2023-0086

BibTeX
@article{Sobh2023,
  author = {Sobh, Eman A and Dahab, Mohammed A and Elkaeed, Eslam B and Alsfouk, Aisha A and Ibrahim, Ibrahim M and Metwaly, Ahmed M and Eissa, Ibrahim H},
  title = {Discovery of New thieno[2,3- d ]pyrimidines as EGFR Tyrosine Kinase Inhibitors for Cancer Treatment},
  journal = {Future Medicinal Chemistry},
  year = {2023},
  doi = {10.4155/fmc-2023-0086}
}
Kostenlos starten →